Remove Licensing Remove Packaging Remove Regulation
article thumbnail

Biopharma Packaging Requirements: What You Need to Know

Pharma Packaging Solutions

As biopharma products become more common, so must biopharma packaging. Due to the sensitive nature of many biological products, there are strict federal regulations in place to ensure safe packaging and distribution. General Regulations (From Section 112.1) General Regulations (From Section 112.1)

article thumbnail

Regulatory Strategy Considerations for Working with the FDA vs the EMA, Part 1

Camargo

However, global regulations are not one-size-fits-all, and sponsors aiming to market their products in multiple regions should be aware of the current standards and processes they may encounter during the development process. Meeting Package Due. Meeting Type. Meeting Purpose. Meeting Timing 1. from receipt of request).

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

PDUFA VII: More Changes Coming in the Latest Reauthorization

Camargo

For a standard new drug application (NDA) for a new molecular entity (NME) or original biologic license application (BLA) pre-approval, the FDA will communicate details on anticipated PMRs to the applicant no later than eight weeks prior to the PDUFA action date. Receipt of Background Package. Response Time. calendar days).

article thumbnail

MIOTIFY platform for digital health products clears AZ road test

pharmaphorum

Teasing out complex relationships within data lies at the heart of any digital health intervention, but finding the algorithms to do so reliably – and making sure they will be acceptable to regulators – can be a challenge. The algorithms used in healthcare are becoming more complex as well.

article thumbnail

Single-Arm Trials Using Real-World Evidence for Rare Disease Product Development

Camargo

Often, to gain clinical trial design insights, a sponsor reviews the physician package inserts from approved New Drug Applications (NDAs) and Biologics License Applications (BLAs) with similar indications or in the same therapeutic area. What is the top regulatory concern when a single-arm study is employed? Simply, BIAS.

article thumbnail

New public Clinical Trials database leads to increased tax & regulatory transparency – risk of supply chain disruption / recall

Pharma Business Blog

Dears Please find hereinafter the latest news related to Clinical Trials in the EU with a respective indirect tax and pharma regulatory licensing impact: 1. The CTIS database is publicly available and leads to increased transparency for indirect tax & pharma regulatory licensing. • What does it mean for you?

article thumbnail

What FDA’s Newest Gene Therapy Approval Tells Us About Durability: How Long is Long Enough?

FDA Law Blog

This product was developed by uniQure prior to being licensed to CSL Behring. However, with this most recent approval, FDA did not leave the question of durability as something to be answered postapproval, which signals to us that this issue looms large in FDA’s preapproval regulation of gene therapies.